Arvinas earnings for the third quarter of 2026 will be reviewed during a live webcast on November 3 at 8:00 a.m. Eastern Time, the biotechnology company announced on October 27. Management also plans to provide a corporate update.

Key Takeaways

  • The webcast will cover third-quarter financial results and a corporate update.
  • A replay will be available on the Arvinas website after the event.

Arvinas earnings webcast details

The presentation will be accessible through the Events and Presentations section of the investor page on the Arvinas website. The announcement did not disclose the quarterly results.

Arvinas is a clinical-stage biotechnology company based in New Haven, Connecticut. Its drug-development platform is designed to use the body’s protein disposal system to remove disease-causing proteins.

Clinical programs and partnerships

The company is advancing investigational drugs for conditions including relapsed or refractory non-Hodgkin lymphoma, neurodegenerative disorders, spinal-bulbar muscular atrophy and advanced solid tumors.

Arvinas has also advanced ARV-806, which targets KRAS G12D for solid tumors, in the clinic. It previously announced plans to seek an out-licensing agreement for additional clinical trials of the drug, including dose-expansion or combination trials.

Arvinas and Pfizer developed the first FDA-approved PROTAC protein degrader, which has been outlicensed to Rigel Pharmaceuticals for exclusive global development, manufacturing and commercialization.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.